Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an update.
Botanix Pharmaceuticals has announced its participation in the annual Euroz Hartleys Institutional Conference, where CEO Dr Howie McKibbon is scheduled to deliver a company presentation. The appearance underscores Botanix’s efforts to raise its profile among institutional investors following FDA approval of Sofdra, positioning the company to highlight its commercial dermatology strategy and growth prospects to key market stakeholders.
The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix that develops treatments for skin conditions. Its lead product, Sofdra, has received U.S. FDA approval as the first and only new chemical entity specifically indicated for primary axillary hyperhidrosis, addressing a significant unmet need for patients with excessive underarm sweating.
Average Trading Volume: 10,157,155
Technical Sentiment Signal: Sell
Current Market Cap: A$104.3M
See more data about BOT stock on TipRanks’ Stock Analysis page.